Catalog No.
DVV03108
Expression system
Mammalian Cells
Species reactivity
Human immunodeficiency virus 1 (HIV-1)
Host species
Human
Isotype
IgG
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
Envelope glycoprotein gp160, Env polyprotein, Surface protein gp120, SU, Glycoprotein 120, gp120, Transmembrane protein gp41, TM, Glycoprotein 41, gp41, env
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q03805
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific
Clone ID
GS-8588
Note
For research use only. Not suitable for clinical or therapeutic use.
The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein., PMID:9813203
Investigations into the cross-reactivity of rabbit antibodies raised against nonhomologous pairs of synthetic peptides derived from HIV-1 gp120 proteins., PMID:9894846
The V3 region of gp120 is responsible for anti-HIV-1 activity of heparin sulphate., PMID:9918507
Increased association of glycoprotein 120-CD4 with HIV type 1 coreceptors in the presence of complex-enhanced anti-CD4 monoclonal antibodies., PMID:10029247
Enhanced HIV type 1 neutralization by human anti-glycoprotein 120 monoclonal antibodies in the presence of monoclonal antibodies to lymphocyte function-associated molecule 1., PMID:10221529
Sendai virus-based production of HIV type 1 subtype B and subtype E envelope glycoprotein 120 antigens and their use for highly sensitive detection of subtype-specific serum antibodies., PMID:10461831
HIV-induced T-cell syncytia release a two component T-helper cell chemoattractant composed of Nef and Tat., PMID:10547354
A genetically engineered spleen necrosis virus-derived retroviral vector that displays the HIV type 1 glycoprotein 120 envelope peptide., PMID:10566890
Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination., PMID:10606091
Anti-CD4-binding domain antibodies complexed with HIV type 1 glycoprotein 120 inhibit CD4+ T cell-proliferative responses to glycoprotein 120., PMID:10875615
Use of human CD4 transgenic mice for studying immunogenicity of HIV-1 envelope protein gp120., PMID:11305358
A defined conformational epitope from the C4 domain of HIV type 1 glycoprotein 120: anti-cyclic C4 antibodies from HIV-positive donors magnify glycoprotein 120 suppression of interleukin 2 produced by T cells., PMID:11350667
Postattachment neutralization of a primary strain of HIV type 1 in peripheral blood mononuclear cells is mediated by CD4-specific antibodies but not by a glycoprotein 120-specific antibody that gives potent standard neutralization., PMID:11779352
CTLA-4 upregulation during HIV infection: association with anergy and possible target for therapeutic intervention., PMID:11872994
Role of N-glycans and SDF-1alpha on the coassociation of CD4 with CXCR4 at the plasma membrane of monocytic cells and blood lymphocytes., PMID:11943153
High levels of antibodies to the CD4 binding domain of human immunodeficiency virus type 1 glycoprotein 120 are associated with faster disease progression., PMID:12134256
Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry., PMID:12218051
In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection., PMID:12574398
Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): production, characterization and immunogenicity., PMID:14505910
HIV-1-infected patients with envelope-specific lymphoproliferation or long-term nonprogression lack antibodies suppressing glycoprotein 120 antigen presentation., PMID:14976603
Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point., PMID:15187026
Human immunodeficiency virus type 1 evades T-helper responses by exploiting antibodies that suppress antigen processing., PMID:15220439
Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp., PMID:15613479
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial., PMID:15688279
CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis., PMID:16046522
HIV-1-mediated syncytium formation promotes cell-to-cell transfer of Tax protein and HTLV-I gene expression., PMID:16413627
Selection and characterization of an HIV-1 gp120-binding affibody ligand., PMID:16712522
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial., PMID:17106277
Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy., PMID:17157668
Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry., PMID:17480119
The differential binding and activity of PRO 2000 against diverse HIV-1 envelopes., PMID:19349871
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand., PMID:19843557
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1., PMID:20616233
Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine., PMID:23089396
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG., PMID:23661056
Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer., PMID:23757493
Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector., PMID:24098600
An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1., PMID:24614107
HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition., PMID:26180102
A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo., PMID:26516768
Cross-Neutralization Activity of Single-Chain Variable Fragment (scFv) Derived from Anti-V3 Monoclonal Antibodies Mediated by Post-Attachment Binding., PMID:26902223
The glycan-mediated mechanism on the interactions of gp120 with CD4 and antibody: Insights from molecular dynamics simulation., PMID:28632942
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans., PMID:31999736
Myomedin replicas of gp120 V3 loop glycan epitopes recognized by PGT121 and PGT126 antibodies as non-cognate antigens for stimulation of HIV-1 broadly neutralizing antibodies., PMID:36569830
Indoline CD4-mimetic compounds mediate potent and broad HIV-1 inhibition and sensitization to antibody-dependent cellular cytotoxicity., PMID:36961924
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120., PMID:37795976
Plasma Human Immunodeficiency Virus 1 Soluble Glycoprotein 120 Association With Correlates of Immune Dysfunction and Inflammation in Antiretroviral Therapy-Treated Individuals With Undetectable Viremia., PMID:38035854
Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial., PMID:38916429
Vaccination of nonhuman primates elicits a broadly neutralizing antibody lineage targeting a quaternary epitope on the HIV-1 Env trimer., PMID:40339576
Immunoinformatic-driven design and evaluation of multi-epitope mRNA vaccine targeting HIV-1 gp120., PMID:40433366
For research use only. Not for human or drug use.
